Skye Bioscience, Valuation
| SKYE Stock | USD 2.86 0.15 4.98% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Skye Bioscience, Common has a current Real Value of $6.68 per share. The regular price of the company is $2.86. Our model measures the value of Skye Bioscience, Common from inspecting the company fundamentals such as Return On Equity of -0.55, shares owned by institutions of 85.41 %, and Shares Outstanding of 30.34 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Skye Bioscience,'s valuation include:
Price Book 1.1446 | Enterprise Value 19.5 M | Enterprise Value Ebitda (2.56) |
Undervalued
Today
Please note that Skye Bioscience,'s price fluctuation is relatively risky at this time. Calculation of the real value of Skye Bioscience, Common is based on 3 months time horizon. Increasing Skye Bioscience,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Skye stock is determined by what a typical buyer is willing to pay for full or partial control of Skye Bioscience, Common. Since Skye Bioscience, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Skye Stock. However, Skye Bioscience,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.86 | Real 6.68 | Target 18.25 | Hype 2.86 |
The real value of Skye Stock, also known as its intrinsic value, is the underlying worth of Skye Bioscience, Common Company, which is reflected in its stock price. It is based on Skye Bioscience,'s financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Skye Bioscience,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Skye Bioscience, Common helps investors to forecast how Skye stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Skye Bioscience, more accurately as focusing exclusively on Skye Bioscience,'s fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Skye Bioscience,'s intrinsic value based on its ongoing forecasts of Skye Bioscience,'s financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Skye Bioscience,'s closest peers. If more than one evaluation category is relevant for Skye Bioscience, we suggest using both methods to arrive at a better estimate.
Skye Bioscience, Cash |
|
Skye Valuation Trend
Comparing Skye Bioscience,'s enterprise value against its market capitalization is a good way to estimate the value of Skye Bioscience, Common uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Skye Bioscience, Total Value Analysis
Skye Bioscience, Common is at this time anticipated to have valuation of 19.55 M with market capitalization of 163.52 M, debt of 4.62 M, and cash on hands of 2.93 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Skye Bioscience, fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
19.55 M | 163.52 M | 4.62 M | 2.93 M |
Skye Bioscience, Asset Utilization
One of the ways to look at asset utilization of Skye is to check how much profit was generated for every dollar of assets it reports. Skye Bioscience, Common has a negative utilization of assets of -0.3 %, losing $0.003039 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Skye Bioscience, Common shows how discouraging it operates for each dollar spent on its assets.Skye Bioscience, Ownership Allocation
Skye Bioscience, Common shows a total of 30.34 Million outstanding shares. The majority of Skye Bioscience, Common outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Skye Bioscience, to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Skye Bioscience, Common. Please pay attention to any change in the institutional holdings of Skye Bioscience, Common as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Skye Bioscience, Profitability Analysis
Net Loss for the year was (37.64 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Skye Bioscience,'s worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Skye Bioscience, and how it compares across the competition.
About Skye Bioscience, Valuation
The stock valuation mechanism determines Skye Bioscience,'s current worth on a weekly basis. Our valuation model uses a comparative analysis of Skye Bioscience,. We calculate exposure to Skye Bioscience,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Skye Bioscience,'s related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -124.3 K | -118 K | |
| Pretax Profit Margin | (0.01) | (0.01) | |
| Operating Profit Margin | (0.41) | (0.39) | |
| Net Loss | (0.41) | (0.39) | |
| Gross Profit Margin | 0.71 | 0.70 |
Skye Bioscience, Growth Indicators
Investing in growth stocks can be very risky. If the company such as Skye Bioscience, does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 7 M |
Skye Bioscience, Current Valuation Indicators
Valuation refers to the process of determining the present value of Skye Bioscience, Common and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Skye we look at many different elements of the entity such as Skye's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Skye Bioscience,, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Skye Bioscience,'s valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Skye Bioscience,'s worth.Complementary Tools for Skye Stock analysis
When running Skye Bioscience,'s price analysis, check to measure Skye Bioscience,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Skye Bioscience, is operating at the current time. Most of Skye Bioscience,'s value examination focuses on studying past and present price action to predict the probability of Skye Bioscience,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Skye Bioscience,'s price. Additionally, you may evaluate how the addition of Skye Bioscience, to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |